Aktiebolaget Hassle & Anor v Alphapharm

The High Court of Australia heard an appeal concerning a dispute between Aktiebolaget Hassle and Alphapharm Pty Ltd. The core of the disagreement revolved around the validity of a patent for a pharmaceutical product, specifically a sustained-release formulation of omeprazole, and whether Alphapharm's generic product infringed that patent. Aktiebolaget Hassle, the patent holder, alleged that Alphapharm's product, which was bioequivalent to their patented formulation, constituted an infringement.

The central legal issues before the High Court were whether the patent was valid, particularly in light of prior art, and if it was valid, whether Alphapharm's product infringed the patent claims. This involved a detailed examination of the patent specifications, the inventive step, and the scope of the claims, as well as the nature of Alphapharm's product and its relationship to the patented invention. The court was required to consider the principles of patent law concerning novelty, inventive step, and infringement in the context of pharmaceutical patents.

The High Court ultimately found that the patent was valid and that Alphapharm's product did infringe the patent. The court's reasoning focused on the interpretation of the patent claims and the evidence presented regarding the inventive step and the prior art. It was determined that the patent disclosed a novel and inventive formulation that provided a significant advantage, and that Alphapharm's product fell within the scope of the patent's claims. The court applied established principles of patent law, including the 'purpose, not just the result' test for infringement, and considered the commercial reality of the pharmaceutical industry.